Loading...

Conatus Pharmaceuticals

DB:CPH
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CPH
DB
$28M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
  • Conatus Pharmaceuticals has significant price volatility in the past 3 months.
CPH Share Price and Events
7 Day Returns
-47.3%
DB:CPH
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-80.9%
DB:CPH
-10.6%
DE Biotechs
-6.2%
DE Market
CPH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Conatus Pharmaceuticals (CPH) -47.3% -77.9% -65.6% -80.9% -78.9% -88.2%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • CPH underperformed the Biotechs industry which returned -10.6% over the past year.
  • CPH underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
CPH
Industry
5yr Volatility vs Market
Related Companies

CPH Value

 Is Conatus Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Conatus Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €0.536.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Conatus Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Conatus Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CPH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.59
NasdaqGM:CNAT Share Price ** NasdaqGM (2019-04-18) in USD $0.83
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Conatus Pharmaceuticals.

DB:CPH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CNAT Share Price ÷ EPS (both in USD)

= 0.83 ÷ -0.59

-1.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Conatus Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Conatus Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Conatus Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:CPH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
56.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Conatus Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Conatus Pharmaceuticals's assets?
Raw Data
DB:CPH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.83
NasdaqGM:CNAT Share Price * NasdaqGM (2019-04-18) in USD $0.83
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:CPH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CNAT Share Price ÷ Book Value per Share (both in USD)

= 0.83 ÷ 0.83

1.01x

* Primary Listing of Conatus Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Conatus Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Conatus Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Conatus Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CPH Future Performance

 How is Conatus Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
56.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Conatus Pharmaceuticals expected to grow at an attractive rate?
  • Conatus Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Conatus Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Conatus Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CPH Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CPH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 56.8%
DB:CPH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 11.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CPH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CPH Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 54 82 78 2
2022-12-31 67 11 23 1
2021-12-31 35 -18 -15 1
2020-12-31 35 -41 -16 1
2019-12-31 33 -22 -16 3
DB:CPH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 34 -35 -18
2018-09-30 35 -36 -18
2018-06-30 37 -31 -18
2018-03-31 38 -33 -19
2017-12-31 35 -33 -17
2017-09-30 27 21 -22
2017-06-30 18 19 -25
2017-03-31 8 26 -26
2016-12-31 1 27 -30
2016-09-30 -24 -27
2016-06-30 -24 -26
2016-03-31 -23 -25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Conatus Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Conatus Pharmaceuticals's revenue is expected to grow by 11.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CPH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Conatus Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CPH Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.19 1.88 0.50 2.00
2022-12-31 0.22 0.48 -0.05 2.00
2021-12-31 -0.25 -0.11 -0.39 2.00
2020-12-31 -0.64 -0.46 -0.82 2.00
2019-12-31 -0.41 -0.21 -0.60 2.00
DB:CPH Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.59
2018-09-30 -0.61
2018-06-30 -0.59
2018-03-31 -0.64
2017-12-31 -0.61
2017-09-30 -0.80
2017-06-30 -0.97
2017-03-31 -1.09
2016-12-31 -1.31
2016-09-30 -1.26
2016-06-30 -1.27
2016-03-31 -1.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Conatus Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Conatus Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Conatus Pharmaceuticals has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CPH Past Performance

  How has Conatus Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Conatus Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Conatus Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Conatus Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Conatus Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Conatus Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Conatus Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CPH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 33.59 -18.01 10.50
2018-09-30 34.98 -18.46 10.27
2018-06-30 36.88 -17.87 10.06
2018-03-31 38.12 -18.79 9.66
2017-12-31 35.38 -17.40 9.71
2017-09-30 27.37 -22.16 10.86
2017-06-30 17.81 -25.03 10.48
2017-03-31 7.80 -26.08 10.52
2016-12-31 0.80 -29.73 10.34
2016-09-30 -26.65 8.68
2016-06-30 -25.85 8.57 -7.95
2016-03-31 -25.44 8.33 -3.88
2015-12-31 -24.15 7.83
2015-09-30 -23.44 7.96 3.39
2015-06-30 -23.81 8.02 15.74
2015-03-31 -23.06 7.87 15.14
2014-12-31 -22.32 7.38
2014-09-30 -21.58 7.58 14.49
2014-06-30 -18.47 6.66 11.98
2014-03-31 -9.62 5.50 9.63
2013-12-31 -4.60 4.65 6.95
2013-09-30 -2.44 3.44 5.48
2013-06-30 -1.70 3.11 5.33
2013-03-31 -7.07 3.09 5.33
2012-12-31 -8.75 3.09 5.53

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Conatus Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Conatus Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Conatus Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Conatus Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Conatus Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CPH Health

 How is Conatus Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Conatus Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Conatus Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Conatus Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Conatus Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Conatus Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Conatus Pharmaceuticals Company Filings, last reported 3 months ago.

DB:CPH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 27.40 0.00 40.69
2018-09-30 16.62 13.72 49.62
2018-06-30 19.97 13.53 57.72
2018-03-31 23.35 13.34 66.75
2017-12-31 28.00 13.16 74.85
2017-09-30 31.28 12.97 85.18
2017-06-30 34.28 12.78 88.20
2017-03-31 19.46 12.59 80.54
2016-12-31 21.79 1.00 77.02
2016-09-30 28.22 1.00 31.06
2016-06-30 27.84 1.00 30.20
2016-03-31 31.35 1.00 32.57
2015-12-31 34.54 1.00 36.51
2015-09-30 39.82 1.00 43.46
2015-06-30 44.38 1.00 48.07
2015-03-31 28.10 1.00 31.00
2014-12-31 33.21 1.00 37.07
2014-09-30 37.77 1.00 41.93
2014-06-30 43.50 1.00 46.96
2014-03-31 48.26 1.00 51.08
2013-12-31 53.12 1.00 56.35
2013-09-30 58.09 1.00 59.59
2013-06-30 1.56 1.98 3.54
2013-03-31 3.51 1.00 5.10
2012-12-31 5.73 1.00 8.03
  • Conatus Pharmaceuticals has no debt.
  • Conatus Pharmaceuticals has no debt compared to 5 years ago when it was 1.9%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Conatus Pharmaceuticals has sufficient cash runway for 1.2 years based on current free cash flow.
  • Conatus Pharmaceuticals has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 25.4% each year.
X
Financial health checks
We assess Conatus Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Conatus Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CPH Dividends

 What is Conatus Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Conatus Pharmaceuticals dividends.
If you bought €2,000 of Conatus Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Conatus Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Conatus Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CPH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CPH Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Conatus Pharmaceuticals has not reported any payouts.
  • Unable to verify if Conatus Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Conatus Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Conatus Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Conatus Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Conatus Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Conatus Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CPH Management

 What is the CEO of Conatus Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steven Mento
COMPENSATION $1,302,997
AGE 66
TENURE AS CEO 13.8 years
CEO Bio

Dr. Steven J. Mento, Ph.D., Co-founded Conatus Pharmaceuticals Inc. in 2005, has been its Chief Executive Officer and President since July 2005. Dr Mento served as an Acting Principal Financial Officer of Conatus Pharmaceuticals Inc. since March 31, 2017 until August 2017. He served as the President and Chief Executive Officer of IDUN Pharmaceuticals, Inc. from August 1997 to 2005. Dr. Mento joined Idun in 1997. From 1982 to 1992, he held various positions at American Cyanamid Company. His last position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid Company. In January 1992, he joined Viagene Inc. as Vice President of Research and Development. He was responsible for directing the American Cyanamid's transition from basic research through initiation of the first company sponsored Phase I and Phase II clinical trials in the emerging field of gene therapy. He served as President of Chiron Viagene Inc. and Vice President of Chiron Corporation until August 1997. As President, he had overall responsibility for gene therapy research, product development, QA/ QC, GMP manufacturing as well as general administration functions at Chiron Viagene. Dr Mento served as a Research Assistant Professor of Medicine and Microbiology at Mount Sinai School of Medicine from 1980 to 1982 before commencing his career in industry. Dr. Mento has over twenty years of combined experience in the biotechnology and pharmaceutical industry, ten of which served as President and Chief Executive Officer. He has been Chairman of Hawaii Biotech, Inc. since April 2007 and has been its Director since December 14, 2006. Dr. Mento served as the Chairman of Conatus Pharmaceuticals Inc. since July 2005 until December 2012. Dr. Mento has been an Independent Director of Sangamo Therapeutics, Inc. since May 24, 2005. He has been a Director of Conatus Pharmaceuticals Inc. since July 2005. He serves as a Director of Biotechnology Industry Organization (BIO). He serves on the Boards of BIOCOM, BIOCOM Institute, BIO Emerging Company Section Governing Body, the BIO Health Section Governing Body, Grannus BioSciences, UCSD-Division of Biological Sciences Board of Advisors, Donald P. Shiley BioScience Center at SDSU Scientific Advisory Board and UCSD Bannister Family House. He served as a Director of IDUN Pharmaceuticals, Inc. from August 1997 to 2005. From 1986 to 1992, he was a Member of the World Health Organization (WHO) Consultative Group on Poliomyelitis Vaccines. In October 1995, Chiron Corporation acquired Viagene Inc., and renamed American Cyanamid as Chiron Viagene Inc. Dr. Mento holds Bachelor of Arts, Master of Science and Ph.D. degrees in Microbiology from Rutgers University. He did his post-doctoral fellowship in somatic cell genetics at the University of Toronto.

CEO Compensation
  • Steven's compensation has increased whilst company is loss making.
  • Steven's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Conatus Pharmaceuticals management team in years:

3.8
Average Tenure
61.5
Average Age
  • The tenure for the Conatus Pharmaceuticals management team is about average.
Management Team

Steven Mento

TITLE
Co-Founder
COMPENSATION
$1M
AGE
66
TENURE
13.8 yrs

Keith Marshall

TITLE
Executive VP
COMPENSATION
$3M
AGE
50
TENURE
1.7 yrs

David Hagerty

TITLE
Executive Vice President of Clinical Development
COMPENSATION
$872K
AGE
63
TENURE
4.5 yrs

Alfred Spada

TITLE
Co-Founder
COMPENSATION
$762K
AGE
60

Alan Engbring

TITLE
Executive Director of Investor Relations & Corporate Communications

Dan Ripley

TITLE
Senior Vice President of Business Development
AGE
57
TENURE
6.8 yrs

Edward Smith

TITLE
Senior Vice President of Regulatory Affairs & Quality Assurance
AGE
64
TENURE
3 yrs

Paul Pockros

TITLE
Special Consultant to the Board of Directors & Member of Advisory Board
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Conatus Pharmaceuticals board of directors in years:

5.8
Average Tenure
68
Average Age
  • The tenure for the Conatus Pharmaceuticals board of directors is about average.
Board of Directors

David Hale

TITLE
Chairman
COMPENSATION
$275K
AGE
69
TENURE
6.3 yrs

Steven Mento

TITLE
Co-Founder
COMPENSATION
$1M
AGE
66
TENURE
13.8 yrs

Hal Van Wart

TITLE
Director
COMPENSATION
$122K
AGE
70
TENURE
12.1 yrs

Paul Pockros

TITLE
Special Consultant to the Board of Directors & Member of Advisory Board

Bill LaRue

TITLE
Director
COMPENSATION
$166K
AGE
67
TENURE
2.2 yrs

Gregory Gores

TITLE
Member of Advisory Board

Scott Friedman

TITLE
Member of Advisory Board

Mitchell Shiffman

TITLE
Member of Advisory Board

Dan Kisner

TITLE
Independent Director
COMPENSATION
$122K
AGE
71
TENURE
5.2 yrs

Preston Klassen

TITLE
Independent Director
COMPENSATION
$119K
AGE
49
TENURE
5.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Conatus Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Conatus Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CPH News

Simply Wall St News

CPH Company Info

Description

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

Details
Name: Conatus Pharmaceuticals Inc.
CPH
Exchange: DB
Founded: 2005
$24,509,493
33,165,122
Website: http://www.conatuspharma.com
Address: Conatus Pharmaceuticals Inc.
16745 West Bernardo Drive,
Suite 200,
San Diego,
California, 92127,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CNAT Common Stock Nasdaq Global Market US USD 25. Jul 2013
DB CPH Common Stock Deutsche Boerse AG DE EUR 25. Jul 2013
Number of employees
Current staff
Staff numbers
31
Conatus Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:50
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/05
Last earnings filing: 2019/03/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.